5-溴吡嗪-2-羧酸甲酯 | 210037-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴吡嗪-2-羧酸甲酯
• 中文别名: 2-溴-5-甲酸甲酯吡嗪；5-溴吡嗪羧酸甲酯
• 英文名称: methyl 5-bromopyrazine-2-carboxylate
• 英文别名: 5-bromopyrazine-2-carboxylic acid methyl ester
• CAS: 210037-58-4
• 化学式: C₆H₅BrN₂O₂
• 分子量: 217.022
• InChiKey: PVTAJWAGBTWOPG-UHFFFAOYSA-N

物化性质

• 沸点：
  289℃
• 密度：
  1.669
• 闪点：
  129℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-bromopyrazine-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-bromopyrazine-2-carboxylate
CAS number: 210037-58-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5BrN2O2
Molecular weight: 217.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴吡嗪-2-羧酸甲酯 在 potassium phosphate 、 copper(l) iodide 、 trans-1,2-cyclohexanediamine 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 为溶剂， 反应 20.0h， 生成 GSK2798745
  参考文献：
  名称：

  [EN] TRPV4 ANTAGONISTS
  [FR] ANTAGONISTES DE TRPV4

  摘要：

  本发明涉及式（I）中的螺环氨基甲酸酯化合物，其中R1，（R2）Y，R3，R4，X和A具有规范中给定的含义。该发明还提供含有这些化合物或其药用可接受盐的药物组合物，并涉及将这些化合物用作TRPV4拮抗剂以治疗或预防与TRPV4失衡相关的疾病。

  公开号：

  WO2013012500A1
• 作为产物：
  描述：

  5-氯吡嗪-2-羧酸甲酯 在 三甲基溴硅烷 作用下， 以 乙腈 为溶剂， 以93%的产率得到5-溴吡嗪-2-羧酸甲酯
  参考文献：
  名称：

  [EN] METHOD FOR PRODUCING 5-(DIFLUOROMETHYL)PYRAZINE-2-CARBOXILIC ACID AND PRODUCTION INTERMEDIATE THEREOF
  [FR] PROCÉDÉ DE PRODUCTION D'ACIDE 5-(DIFLUOROMÉTHYL)PYRAZINE-2-CARBOXYLIQUE ET D'UN INTERMÉDIAIRE POUR SA PRODUCTION

  摘要：

  5-(二氟甲基)吡啶-2-羧酸是构建5-(二氟甲基)吡啶-2-羧酰胺的原料，后者是具有A类生产抑制作用或BACE1抑制作用的化合物的常见部分结构基团，可以通过脱羧5-[羧基(二氟甲基)甲基]吡啶-2-羧酸来工业上有利地生产，后者可从5-氯吡啶-2-羧酸酯获得。

  公开号：

  WO2013162065A1

文献信息

• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193063A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾患和症状的化合物、组合物和方法。
• HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US20180098990A1

  公开（公告）日：2018-04-12

  A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.

  本发明涉及一种具有组蛋白去乙酰化酶抑制活性的4-芳氨基喹唑啉羟胺酸化合物、其制备方法、包含该化合物的药物组合物，以及该化合物和药物组合物在制备组蛋白去乙酰化酶抑制剂药物中的用途。本发明的目的是通过药物设计和合成技术，基于优化4-芳氨基喹唑啉的酶表面识别区域和连接区域，获得一系列具有良好低类型选择性和有利药代动力学特性的选择性组蛋白去乙酰化酶抑制剂，从而在提高正常组织或细胞的抗肿瘤活性的同时，减少对正常组织或细胞的影响。
• PIPERIDINE DERIVATIVES FOR GPR119 AGONIST
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US20150166480A1

  公开（公告）日：2015-06-18

  The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

  本发明涉及新型的哌啶衍生物、它们的立体异构体或药用可接受的盐；制备该化合物的方法；以及包含该化合物的药物组合物。根据本发明，具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢紊乱，包括糖尿病（尤其是II型）及相关疾病。
• FUSED HETEROCYCLYC INHIBITOR COMPOUNDS
  申请人：Melvin, JR. Lawrence S.

  公开号：US20100029638A1

  公开（公告）日：2010-02-04

  The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

  本发明提供了一种具有组蛋白去乙酰化酶（HDAC）和/或 Cyclin 依赖性激酶（CDK）抑制活性的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的方法。
• Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology
  作者：Timo Heinrich、Ada Sala-Hojman、Roberta Ferretti、Carl Petersson、Stefano Minguzzi、Andrzej Gondela、Shivapriya Ramaswamy、Anna Bartosik、Frank Czauderna、Lindsey Crowley、Pamela Wahra、Heike Schilke、Pia Böpple、Łukasz Dudek、Marcin Leś、Paulina Niedziejko、Kamila Olech、Henryk Pawlik、Łukasz Włoszczak、Karol Zuchowicz、Jose Ramon Suarez Alvarez、Justyna Martyka、Ewa Sitek、Maciej Mikulski、Joanna Szczęśniak、Sven Jäckel、Mireille Krier、Marcin Król、Ansgar Wegener、Michał Gałęzowski、Mateusz Nowak、Frank Becker、Christian Herhaus

  DOI：10.1021/acs.jmedchem.1c00448

  日期：2021.8.26

  Due to increased lactate production during glucose metabolism, tumor cells heavily rely on efficient lactate transport to avoid intracellular lactate accumulation and acidification. Monocarboxylate transporter 4 (MCT4/SLC16A3) is a lactate transporter that plays a central role in tumor pH modulation. The discovery and optimization of a novel class of MCT4 inhibitors (hit 9a), identified by a cellular

  由于葡萄糖代谢过程中乳酸产生增加，肿瘤细胞严重依赖有效的乳酸转运来避免细胞内乳酸积累和酸化。单羧酸转运蛋白 4 (MCT4/SLC16A3) 是一种乳酸转运蛋白，在肿瘤 pH 调节中发挥核心作用。描述了通过 MDA-MB-231 细胞筛选鉴定的一类新型 MCT4 抑制剂（命中9a ）的发现和优化。在溶解 GFP 标记的转运蛋白后，通过荧光互相关光谱和显微镜研究显示了优化化合物18n与 MCT4 胞质结构域的直接靶相互作用。体外用18n处理可抑制 MCT4 高表达细胞的乳酸外流并降低细胞活力。此外， 18n的药代动力学特性允许在小鼠肿瘤模型中评估乳酸调节和抗肿瘤活性。因此， 18n是研究选择性 MCT4 抑制及其对肿瘤生物学影响的宝贵工具。